CANCER TREATMENT REVIEWS

Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.

Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives.

Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application.

Hedgehog signaling inhibitors in solid and hematological cancers.

Checkpoint inhibitors in pancreatic cancer.

Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.

eHealth for improving quality of life in breast cancer patients: A systematic review.

EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis.

Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies.

Proton therapy for treatment of intracranial benign tumors in adults: A systematic review.

Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.

Management of metastatic bladder cancer.

B cell and B cell-related pathways for novel cancer treatments.

Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence.

Comparison and applicability of molecular classifications for gastric cancer.

Oligometastatic prostate cancer: The game is afoot.

Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives.

Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling.

FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma.

Therapeutic landscape of metaplastic breast cancer.

A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma.

Vulvar malignant melanoma: Pathogenesis, clinical behaviour and management: Review of the literature.

Aggressive variants of prostate cancer - Are we ready to apply specific treatment right now?

Opportunities of circulating tumor DNA in lung cancer.

Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma.

Androgen receptor plasticity and its implications for prostate cancer therapy.

Innovation in oncology clinical trial design.

Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation.

Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications.

Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes.

Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.

Liquid biopsy for rectal cancer: A systematic review.

Multiple myeloma: Role of autologous transplantation.

Systematic review and meta-analysis of patient reported outcomes for nurse-led models of survivorship care for adult cancer patients.

Trametinib in the treatment of multiple malignancies harboring MEK1 mutations.

Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis.

The role of PET/CT in the modern treatment of Hodgkin lymphoma.

Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma.

Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis.

Breast cancer vaccines: Heeding the lessons of the past to guide a path forward.

Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice.

Should we favour the use of 5\u202f×\u202f5 preoperative radiation in rectal cancer.

Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors.

Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer.

Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients.

Grey areas and evidence gaps in the management of rectal cancer as revealed by comparing recommendations from clinical guidelines.

Small cell and large cell neuroendocrine carcinoma of the larynx: A comparative analysis.